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Abstract: Epidemiological results revealed that there is an inverse correlation between high-density
lipoprotein (HDL) cholesterol levels and risks of atherosclerotic cardiovascular disease (ASCVD).
Mounting evidence supports that HDLs are atheroprotective, therefore, many therapeutic approaches
have been developed to increase HDL cholesterol (HDL-C) levels. Nevertheless, HDL-raising therapies,
such as cholesteryl ester transfer protein (CETP) inhibitors, failed to ameliorate cardiovascular
outcomes in clinical trials, thereby casting doubt on the treatment of cardiovascular disease (CVD)
by increasing HDL-C levels. Therefore, HDL-targeted interventional studies were shifted to
increasing the number of HDL particles capable of promoting ATP-binding cassette transporter A1
(ABCA1)-mediated cholesterol eﬄux. One such approach was the development of reconstituted HDL
(rHDL) particles that promote ABCA1-mediated cholesterol eﬄux from lipid-enriched macrophages.
Here, we explore the manipulation of rHDL nanoparticles as a strategy for the treatment of CVD. In
addition, we discuss technological capabilities and the challenge of relating preclinical in vivo mice
research to clinical studies. Finally, by drawing lessons from developing rHDL nanoparticles, we also
incorporate the viabilities and advantages of the development of a molecular imaging probe with
HDL nanoparticles when applied to ASCVD, as well as gaps in technology and knowledge required
for putting the HDL-targeted therapeutics into full gear.
Keywords: apolipoproteins and inflammatory properties; ABCA1; reconstituted high-density
lipoprotein; cardiovascular disease; molecular imaging
1. Introduction
Epidemiological studies identified several independent risk factors for cardiovascular disease
(CVD), including hypertension, age, smoking, insulin resistance, elevated low-density lipoprotein
cholesterol (LDL-C) levels, and triglyceride levels [1]. The majority of people establish plaques during
young adulthood, making plaque regression the optimal therapeutic strategy [2–5]. The most effective
LDL lowering agent, PCSK9 inhibitor evolocumab, only regressed coronary atheroma volume as
assessed by serial coronary intravascular ultrasound by 0.95%, although 78 weeks of treatment reduced
the LDL-C to 36.6 mg/dL in humans [6,7]. Clinical studies confirm that apolipoprotein AI (apoAI) can
largely promote the regression of atherosclerosis by increasing functional high-density lipoprotein
(HDL) particles [8–12].
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2. Atheroprotective Functions of HDL
Additional evidence for the atheroprotective effects of apoAI or HDL derives from mouse models
of experimental atherosclerosis and clinical trials. One of the most effective approaches is to promote
new HDL particle formation by enhancing endogenous production of apoAI, which is supported by
using human apoAI transgenic mice studies as well as virus-mediated overexpression of apoAI in
a mouse model of experimental atherosclerosis [13–15]. In addition, RVX-208, a bromodomain and
extraterminal domain (BET) protein inhibitor, is able to increase the production of apoAI [14,16,17].
A recent study found that RVX-208 significantly reduces major adverse cardiovascular events (MACE)
in diabetes patients with CVD although administration of RVX-208 did not promote the regression of
coronary atheroma due to its moderate effect on raising HDL-C levels in patients with CVD [17,18].
Similarly, RVX-208 treatment decreased circulating levels of vascular inflammation mediators, such as
adhesion molecules, tumor necrosis factor α (TNFα), and interleukin 1β I(L-1β) in CVD patients [19].
Inhibition of the inflammation-induced adhesion molecule gene expression by RVX-208 may contribute
to MACE reduction in the phase III clinical trial. Therefore, the identification of novel molecules
that regulate apoAI synthesis is essential for increasing apoAI and HDL production and improving
vascular inflammation.
HDL protective functions, including anti-inflammatory and mediation of reverse cholesterol
transport (RCT), likely contribute to the regression of established plaques and are central in protecting
against CVD [20,21]. For example, HDLs can prevent LDL-induced monocyte migration and inhibit
the expression of pro-inflammatory cytokines [22]. This anti-inflammatory property is partly due
to HDL-associated proteins, such as platelet-activating factor acetylhydrolase and paraoxonase1
(PON1) [23,24]. Importantly, recent studies demonstrate that HDL-cholesterol (HDL-C) levels are
inversely associated with risks of CVD [9,25–27]. In addition, it is reported that HDL function is
impaired in familial hypercholesterolemic (FH) patients [28,29]. HDL recirculation through tissues
is limited in experimental psoriasis, potentially leading to the development of atherosclerosis [30],
and there is abundant dysfunctional apoAI in human atherosclerotic lesions [31,32]. Therefore,
HDL-targeted therapy is a promising approach for the treatment of CVD.
Much progress has been made to increase HDL-C levels in plasma using orally-administered small
molecules such as niacin and cholesteryl ester transfer protein (CETP) inhibitors [33,34]. Large-scale
human clinical studies demonstrated that HDL-targeted therapy, such as niacin, failed to show a
clinical benefit by raising HDL-C levels when combined with statin therapy (nicely reviewed in [20,33]).
The development of CETP inhibitors has had a long road with three compounds either halted earlier
or ineffective in phase III clinical trials. The latest REVEAL (randomized evaluation of the effects of
anacetrapib through lipid modification) study showed that anacetrapib increased HDL-C levels and
reduced coronary heart disease when combined with statin therapy [35]. The efficacy of anacetrapib
seems to be partially due to the reduction in non-HDL-C, rather than an increase of HDL-C levels.
On the other hand, these compounds may interfere with the lipid metabolism and cause alterations
in HDL structure and HDL-C composition [36]. The changed composition of HDL subpopulations
is directly related to their cardioprotective functions. HDLs have any combination of nearly 90
different proteins and the HDL-C measurement only provides the values of cholesterol or its ester
within the HDL complex, and is only made up of 20% of the HDL [37,38]. There is no doubt that the
atheroprotective functions of HDLs could change after raising cholesterol levels on the HDL complex.
These HDL-C-raising trials that interrupted HDL catabolism to increase HDL-C, ultimately resulted
in production of large cholesteryl ester-enriched particles. Compared to small dense human HDL3
particles, large HDL particles may not interact efficiently with the ATP binding cassette transporter
A1 (ABCA1) and ABCG1 [36]. This turns out to be essential, given that the interaction with ABCA1
and ABCG1 plays an important role in promoting cholesterol eﬄux to HDLs from macrophages. In
addition, pharmacologically raising HDL-C levels with niacin and CETP inhibitors may affect HDL
subsets, cause an increase in cholesterol levels in HDLs, and increase the size of the HDL particle, which
may counteract or offset the HDL’s beneficial effects [39–41]. Supporting these notions, a recent study
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demonstrated that CETP inhibitor gives rise to fatty liver and insulin resistance in CETP-expressing
transgenic mice fed with a high-fat diet [42]. Recent studies provide solid evidence that HDL eﬄux
capacity is inversely related to cardiovascular events after being adjusted with other risk factors,
including HDL-C levels [26,27]. Therefore, studies to restore HDL functions are needed to increase the
number of particles capable of promoting ABCA1-mediated cholesterol eﬄux.
3. Therapeutic Approaches Targeting Increasing HDL Particles
Recent failures of CETP inhibition aimed at increasing HDL-C levels to decrease the risk of CVD
have shifted the focus of HDL research towards a better understanding of mechanisms to preserve
HDL function(s), rather than raising HDL-C levels. HDLs mediate the transport of cholesterol from
peripheral tissues to the liver from which it can be secreted as bile acid, the process of which is known
as reverse cholesterol transport (RCT). There are basically three steps in this process: (1) cholesterol
eﬄux, where apoAI and HDLs interact with ABCA1 and ABCG1 to remove excess cholesterol from
lipid-enriched macrophages as shown in Figure 1; (2) lipoprotein remodeling after accepting cholesterol
and HDLs with structural modifications; and (3) cholesterol uptake by scavenger receptor class B type
I (SR-BI) expressed in the liver, where cholesterol is converted into bile acid for the final excretion into
bile and feces [43,44].
Figure 1. In vivo reverse cholesterol transport (RCT) pathway. Modified low-density lipoproteins
(LDLs) are recognized by scavenger receptor A (SRA) and taken up by macrophages, which lead to
the formation of a foam cell. Apolipoprotein AI (ApoAI) or nascent high-density lipoproteins (HDLs)
promote the cholesterol eﬄux from foam cells by interacting with ATP-binding cassette transporters
(ABC1) ABCA1 or ABCG1. Free cholesterol in HDLs is esterified into cholesteryl ester (CE) by lecithin
cholesterol acyltransferase (LCAT) to produce the mature HDL. Liver scavenger receptor class B
type I (SR-BI) is responsible for recognition of HDLs and promotes the uptake of cholesterol. CE
is de-esterified and converted into bile acid, which is secreted into the bile. In humans, CE can be
transported onto ApoB by cholesterol ester transport protein (CETP) and leads to the formation of
LDLs or very low-density lipoproteins (VLDLs).
4. ApoAI Mimetic Peptide
Recent studies suggest that apoAI mimetic peptides serve as a promising new therapeutic approach
by promoting the formation of pre-β HDLs, increasing cholesterol eﬄux, and preventing lipoprotein
oxidation [45]. The sequence of 18A (D-W-l-K-A-F-Y-D-K-V-A-E-K-l-K-E-A-F) does not have any
sequence homology to apoAI, but has the ability to display a class A amphipathic helix similar to those
found in apoAI, which is the determinant of the lipid-binding properties. Among the most extensively
studied apoAI mimetic peptides is the 4F peptides (Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2).
ApoAI mimetic 4F peptides were synthesized from both all D-amino acids (D-4F) and all L-amino
acids (L-4F). The apoAI mimetic 4F peptide exhibited a remarkable binding affinity for oxidized lipids
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compared to the wild type apoAI [46]. Treatment with D-4F increased RCT from macrophages in
Apoe−/− mice [47]. In addition, Rev-D4F was developed to determine its effect on atherosclerosis.
Interestingly, Rev-D4F reduced the atherosclerotic lesion and macrophage content without altering
the HDL-cholesterol levels in Apoe−/− mice. Rev-D4F also prevented LDL oxidation, reduced the
expressions of endothelial cell vascular cell adhesion molecule 1 (VCAM-1) and monocyte chemotactic
factor 1 (MCP-1), and improved vascular inflammation in Apoe−/− mice [48]. More importantly,
the recent randomized controlled clinical trial demonstrated that oral apoAI mimetic D-4F reduced
the HDL inflammatory index in high-risk patients [49]. Taken together, these results support the
development of apoAI mimetic peptides as a therapeutic approach for the treatment of atherosclerosis.
5. Reconstituted High-Density Lipoprotein (rHDL) Nanoparticles
Proteomic studies found HDLs contain hundreds of proteins and lipids [10]. Therefore, HDLs are
highly heterogeneous. Using rHDLs as a tool allows us to better understand HDL composition and its
roles in CVD. rHDLs are synthesized by the combination of apoAI and phospholipids (Figure 2). The
biochemical properties of the rHDL particles are determined using transmission electron microscopy
(TEM), atomic force microscopy (AFM), dynamic light scattering (DLS), and circular dichroism (CD)
spectroscopy after purification with fast protein liquid chromatography (FPLC) [50]. It is reported that
three different apoAI have been utilized to synthesize rHDLs, including human apoAI de-lipidated
from HDLs, recombined human apoAI purified from Escherichia coli, and synthesized apoAI peptides.
Development of rHDL nanoparticles that mimic pre-β HDLs, could promote cholesterol eﬄux from
lipid-enriched macrophages, thereby reducing atherosclerosis. Many different rHDL nanoparticles
(apoAI-bound phospholipid disks or delipidated HDL particles, mutant apoAI proteins, and apoAI
mimetic peptides) have been constructed and investigated in animal studies and human clinical
trials [51].
Figure 2. Synthesis and characterizations of rHDL and rHDL imaging probes. rHDLs are made up of
reconstituted apoAI and phospholipids. rHDLs are characterized by biochemical approaches such as
polyacrylamide gel electrophoresis (PAGE) analysis, and transmission electron microscopy (TEM) or
atomic force microscopy (AFM) for measuring dimensions of rHDL nanoparticles after purification
with fast protein liquid chromatography (FPLC). The biophysical properties of the rHDL particles is
determined by using dynamic light scattering (DLS) and circular dichroism (CD) spectroscopy. rHDLs
can be labeled with fluorescent dye or MRI imaging contrast agents for in vivo imaging purposes.
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6. Reconstituted ApoAI Milano/Palmitoyl-Oleoyl Phosphatidyl Choline (POPC)
Emerging therapeutic approaches targeting rHDL have been investigated to reduce the risk of
cardiovascular events in the past decades [52,53]. One of the important therapies is apoAI Milano
(apoA-IM), a naturally occurring mutant of apoAI that was shown to be related with cardioprotective
effects [54]. Therefore, the first human recombinant apoA-IM ETC-216 was developed by the
combination of the recombinant apoAI Milano with POPC (mass ratio is 1:1.1). Preclinical studies
demonstrated that the recombinant apoA-IM increased cholesterol eﬄux from macrophages and RCT,
and reduced atherosclerotic plaques in mice [55]. Interestingly, the recombinant HDLs (Milano) exert
greater anti-inflammatory and plaque stabilizing properties than wild-type HDLs [56]. In vitro studies
demonstrated that the apoA-IM protein dramatically inhibited expression of cycloxygenase (COX)-2
and MCP-1 in macrophages compared to wild-type apoAI [57]. Further, infusion of recombinant
apoAI Milano-phospholipid complexes causes rapid regression of atherosclerosis. Infusion of rHDLs
(Milano) significantly induce a greater aortic plaque regression compared to wild-type HDL treatment
in a rabbit model examined by magnetic resonance imaging (MRI) [57]. More importantly, infusion
of ETC-216 was related to a significant reduction of the atherosclerotic plaque in patients with acute
coronary syndrome (ACS) [56]. Unfortunately, the clinical trial was discontinued because a serious
adverse reaction (dose-dependent increases in neutrophils and decreases in lymphocytes) occurred
due to small quantities of residual host cell proteins (HCPs).
7. MDCO-216
To overcome the adverse effects of ETC-216, another recombinant apoA-IM, MDCO-216, was
developed and its efficacy was examined in patients with coronary artery disease [58,59]. MDCO-216
infusion reduced small HDLs and resulted in the production of α-1 and α-2 HDLs containing both
wild-type apoAI and apoAI Milano. Administration of MDCO-216 (ApoA-1 Milano/POPC) promoted
ABCA1-mediated cholesterol eﬄux and pre-β HDLs in healthy volunteers and patients with stable
coronary artery disease [60,61]. Subsequently, HDL mimetic containing the recombinant apoAI Milano
(five weekly infusion of MDCO-216) was developed to determine its effect on coronary disease in
patients with an acute coronary syndrome in the MILANO-PILOT trial [62]. However, administration
of MDCO-216 failed to promote the regression of the atherosclerotic plaque when combined with statin
therapy [62].
8. CER-001
CER-001 was made by recombinant human apoAI, sphingomyelin (SPM), and
dipalmitoylphosphatidyl glycerol (DPPG) (protein to phospholipid = 1:2.7). CER-001 increased
the reverse lipid transport and promoted atherosclerosis regression in Ldlr−/− mice. More importantly,
there was a significant reduction in macrophage content and a reduction in VCAM-1 expression in the
plaque after treatment of mice with CER-001 [63]. However, six weekly infusions of HDL-mimetic
agent CER-001 did not regress atherosclerosis measured by intravascular ultrasonography (IVUS) [64].
Similarly, in another trial, 10 weekly infusions of CER-001 failed to promote the regression of coronary
atherosclerosis in statin-treated patients with ACS and high plaque burden [65].
9. CSL-111
CSL-111, a reconstituted HDL particle, is combined by native apoAI and phospholipids. Recent
studies demonstrate that rHDL CSL-111 infusion reduced the total number of circulating leucocytes
and neutrophils in mice following ischemic reperfusion (I/R) [66,67]. CSL-111 reduced the number of
circulating monocytes and B lymphocytes and improved post-ischemic heart function through the
modulation of acute inflammatory response [66,68]. rHDL reduced the percentage of B lymphocytes
recruited into the heart of mice on a high-fat diet (HFD), stressing its remarkable anti-inflammatory
function. However, in a human clinical study, CSL-111 failed to reduce the volume of atherosclerotic
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plaque, but it did improve the plaque characterization index and coronary score by quantitative
coronary angiography (QCA), thereby suggesting therapeutic potential [69]. CSL-111 was halted from
development due to the increase of liver enzymes [69].
10. CSL-112
A new formulation of human rHDL CSL-112 was developed by reconstituting human
plasma-derived apoAI with phosphatidylcholine to form disc-shaped HDL particles. There are
two molecules of human apoAI, about 110 molecules of phosphatidylcholine and sucrose as a
stabilizing agent. CSL-112 significantly increased the cholesterol eﬄux from J774 macrophages [70].
Infusion of CSL-112 was shown in several studies to modify plaque characterization on IVUS [69,71].
CSL-112 increased RCT and modified plaque lipid composition. These results support the continued
evaluation of the safety and efficacy of CSL-112 as a new therapy for patients with ACS. However,
larger populations are needed to determine the clinical efficacy of CSL-112 in ACS patients with a
higher risk of adverse events. A large phase III study (NCT03473223) is currently recruiting patients
and is expected to be concluded in 2022. Whether or not a long-term study of CSL-112 in large
populations is able to reduce CAD risk will be determined.
These major rHDL-based therapies (MDCO-216, CER-001, and CSL-112) are remarkably different
in composition, dosing, pharmacokinetics, and pharmacodynamics as shown in Table 1. There may be
many multifactorial reasons for the failure of the rHDL-targeted therapy. First of all, the duration of
the study could have been too short. In addition, the dosage could have been too low to be effective
or not frequent enough; thus, potentially beneficial effects of administration of rHDLs in the long
term could have been neglected. Moreover, it is known that oxidative stress and inflammation readily
change HDL composition and function [72]. Post-translational modifications, phospholipid depletion,
and enrichment with proinflammatory proteins like serum amyloid A (SAA) or myeloperoxidase
(MPO) may change its atheroprotective function after administration of rHDLs [73–75]. Moreover,
the phosphatidylcholine moiety of the rHDL nanoparticles may be immediately degraded in plasma,
generating lysophospholipids that might alter the functions of HDLs [36].
Table 1. Reconstituted HDL nanoparticles studied in clinical trials.
Mimetic Protein toPhospholipid Ratio Dose Duration Population Size Clinical Outcomes Reference
ETC-216
reconstituted apoAI
Milano/POPC
complex = 1:1.1
5 weekly infusions of
ETC-216 at 45 mg/kg n = 47
Modest regression of
coronary plaque in the
individual
[56]
MDCO-216
reconstituted apoAI
Milano/POPC
complex = 1:1.1
5 weekly, 20 mg/kg
(n = 59) placebo (n =
67) in statin-treated
patients
Failed to produce an
incremental plaque
regression in statin
therapy
[62]
CER-001
reconstituted human
apoAI to SPM and
DPPG (32:1) = 1:2.7
10 weekly, 3 mg/kg,
in addition to statins
CER-001 (n = 135) or
placebo (n = 137) in
patients with ACS
Failed to promote
regression of coronary
atherosclerosis
[65]
CER-001
recombinant human
apoAI to SPM and
DPPG (32:1) = 1:2.7
6 weekly, 12 mg/kg placebo n = 113,CER-001 n = 100
Failed to reduce
coronary
atherosclerosis on
IVUS
[64]
CSL-111
human apoAI with
soybean
phosphatidylcholine
(CSL-111)
4 weekly, 40 mg/kg,
80 mg/kg n = 111
Significant
improvement in the
plaque
characterization index
[69]
CSL-112
plasma-derived
apoAI to mixed PCs
isolated from
soybean = 1:1.4
weekly infusions of
CSL-112
Results to be
concluded in 2022
CSL-112 are feasible,
well tolerated [71]
POPC: palmitoyl-oleoyl phosphatidyl choline; SPM: sphingomyelin; DPPG: dipalmitoylphosphatidyl glycerol;
IVUS: intravascular ultrasonography; ACS: acute coronary syndrome; PCs: phosphatidylcholines.
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11. rHDL Nanoparticles as a Drug Delivery Vehicle
The application of rHDL nanoparticles for delivering therapeutic compounds for the treatment
of cancer has been studied extensively [76–78]. Recent studies show that rHDL nanoparticle serve
as a drug delivery system to deliver compounds efficiently into macrophages and atherosclerotic
plaques [79]. To investigate the immunomodulatory drugs for atherosclerosis, several nanoparticles
were developed to increase the specificity of the drug delivery. rHDLs were efficiently used to deliver
a liver X receptors (LXR) agonist GW3965 to atherosclerotic plaques of Apoe−/− mice [80]. Importantly,
rHDLs loaded with GW3965 completely abolished the liver toxicity of GW3965 in a one-week intensive
treatment regimen in atherosclerotic mice. The long-term treatment with rHDLs significantly reduced
atherosclerotic plaques in Apoe−/− mice [81].
Statins have potent anti-inflammatory functions, but these cannot be fully exploited with oral
statin therapy owing to a low systemic bioavailability. Interestingly, an injectable rHDL nanoparticle
was synthesized to deliver simvastatin, and the effect of simvastatin-rHDL on atherosclerotic plaques
was examined in mice. This study demonstrates that statin-loaded reconstituted HDL nanoparticles
improved inflammation in atherosclerotic plaque [82]. More interestingly, nanoparticle-based delivery
of simvastatin inhibited plaque macrophage proliferation in Apoe−/− mice with advanced atherosclerotic
plaques [83]. rHDL nanoparticles increased the plasma half-life of statins to 20 h. In addition, a recent
study showed that rHDL-mediated targeted delivery of the LXR agonist promoted atherosclerosis
regression [84].
Arachidonic acid (AA) was engineered into the rHDL complex to increase the efficacy of statins.
AA-LT-rHDL (arachidonic acid-lovastatin-rHDL) exhibited lower reactivity with LCAT and more
potent inhibition effects on foam cell formation in the presence of LCAT because of less undesired LT
leakage during the remodeling of rHDLs induced by LCAT and more cellular drug uptake [85]. In
addition, increasing AA concentration in AA-LT-rHDL particles reduced intracellular lipid deposition,
decreased intracellular cholesterol esters content, and DiI-oxLDL uptake, and inhibited the expressions
of pro-inflammatory cytokines TNF-α and IL-6 [85]. Together, these results proved that AA modification
prevented the reactivity of LT-rHDL with LCAT, thereby inhibiting the undesired drug leakage during
rHDL remodeling induced by LCAT. To better fulfill the targeted-delivery of rHDL, it might be
interesting to determine whether the efficacy of the incorporation of AA into LT-rHDL is better than
LT-rHDL for the treatment of atherosclerosis in mice. It would also be intriguing to investigate whether
the polyunsaturated fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have
better efficacy than AA in preventing LCAT-induced degradation of rHDL.
12. Delivery of Oligonucleotides Using rHDL Nanoparticles
HDLs are highly heterogeneous and transport a large variety of lipids, proteins, and
microRNAs [86]. Anti-sense nucleotides and siRNA(s) are widely used to modulate gene expression
and are being considered for therapeutics of atherosclerosis [87–89]. One of the major issues is
that the half-life of anti-sense nucleotides is usually low in the presence of serum nucleases [90].
In addition, the therapeutic efficiency of nucleic acids is relatively low owing to the non-specific
bio-distribution and subsequent off-target effects of nucleotides. Recent studies demonstrate that HDLs
are natural at carrying nucleotides and transporting nucleotides specifically to recipient cells [91].
Moreover, HDL-miRNA cargoes from atherosclerotic patients induced remarkable gene expression,
with substantial loss of conserved mRNA targets in hepatocytes. Collectively, these results show that
HDL is involved in a mechanism of intercellular communication by transporting and specific delivery
of miRNAs to cells. Therefore, rHDLs are believed to be an efficient vehicle for the specific delivery of
siRNA and other anti-sense nucleotides for therapeutic applications [76,92].
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13. Molecular Imaging of rHDL-Based Nanoparticles in Atherosclerosis
Mounting evidence shows that early stages of the lesion development is dominant by monocyte
recruitment followed by monocyte differentiation into macrophages in mice, whereas macrophage
proliferation is more predominant in advanced atherosclerotic plaques [43,93,94]. Molecular imaging
approaches are developed to detect macrophage inflammation and lipid accumulation [95,96]. Immune
cells such as neutrophils and monocytes are major sources of peroxidases because these enzymes are
stored in granules, such as myeloperoxidase (MPO). MPO plays important roles in the inflammatory
response and perpetuation of chronic inflammation in atherosclerosis [75]. Inactivation of MPO reduced
reactive oxygen species (ROS)-mediated vascular inflammation and atherosclerosis [97–99]. Several
imaging agents targeting myeloperoxidase were developed to monitor the inflammatory response
and macrophage accumulation [75,100–102]. rHDLs were recently developed as imaging agents due
to their ability of specific delivery to macrophages [51,103]. Interestingly, superparamagnetic rHDL
nanoparticles were developed for magnetically-guided drug delivery and lipoprotein drug delivery
through magnetic targeting which have shown to be effective chemotherapeutic approaches for prostate
cancer [104]. Recent studies demonstrate that this nanomedicine-based delivery strategy based on
rHDL nanoparticles also allows for the delivery of compounds to atherosclerotic plaque. Statin-rHDL
ameliorates plaque inflammation and opens a new field for atherosclerosis nanotherapy [82]. S-rHDL
labeled with Cy5.5 (lipid monolayer) and DiR (hydrophobic core) show that Cy5.5 and DiR were
accumulated and detected in the atherosclerotic lesions [82]. Similarly, HDL mimetic CER-001
was radiolabeled with 89Zr to allow for imaging macrophage accumulation and positron emission
tomography–computed tomography (PET/CT) imaging [105].
LXRs, oxysterol-activated nuclear receptors, play an important role in RCT through promoting
ABCA1 and/or ABCG1-mediated cholesterol eﬄux. In vivo PET imaging probes radiolabeled with
zirconium-89 (89Zr) on discoidal HDL nanoparticles were made by the reconstituting apoAI and
the phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphocholine, the chelator deferoxamine B, and
89Zr [106]. It was demonstrated that the radioactivity in atherosclerotic aortas of rabbits was more
than three-fold higher than the control animals after the injection with 89Zr-HDL nanoparticles. There
was increased accumulation of radioactivity in lesions measured by the in vivo PET imaging [106].
Therefore, rHDLs demonstrated to be a reliable imaging probe and this allows us to study its in vivo
properties to visualize the macrophage accumulation in advanced atherosclerotic lesions by using
noninvasive PET imaging [106].
14. Concluding Remarks
HDL-targeted drug CETP inhibitors except anacetrapib did not decrease cardiovascular events in
clinical trials. Convincing results demonstrate that increased HDL cholesterol levels do not always
correlate with enhanced protective HDL properties [39–41], thus questioning its potential as a biomarker
of HDL functionality. In addition, the association between low levels of HDL-C and CVD may be
confounded by other factors, such as insulin resistance, inflammation, and/or metabolic derangements
leading to altered plasma lipids. Importantly, current research is focused on both developing robust
HDL functional assays and determining specific proteins or lipid molecules within the HDL complex
to promote cholesterol eﬄux capacity for future translational and pre-clinical studies.
Although several rHDL nanoparticles failed to regress the atherosclerotic plaques in humans, it
should be noted that these clinical trials are relatively short-term studies; the duration of these trials
was only 4–6 weeks. There is solid evidence that HDL beneficial effects have to do more with the
achievement of a continuous flux and steady export of cholesterol, rather than absolute levels of HDL
cholesterol [36]. Whether rHDL nanoparticles would be more effective for the treatment of coronary
artery disease over a longer period of time remains to be investigated. Furthermore, the field of rHDL
nanoparticles has developed considerably and is poised for a big leap with the application of drug
delivery systems and technologies that enable the specific delivery of new compounds to the biological
system [107]. In conclusion, recent advances on rHDL nanoparticles have opened up a new avenue by
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which to ameliorate the inflammatory response for the treatment of CVD. Better understanding of
the functional roles of HDL will likely lead to new approaches to battle and monitor the expanding
burden of CVD.
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AA Arachidonic acid
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COX-2 Cycloxygenase-2
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ApoAI Apolipoprotein AI
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ApoB Apolipoprotein B
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DPPG Dipalmitoylphosphatidyl glycerol
HCP Host cell proteins
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REVEAL Randomized Evaluation of the Effects of Anacetrapib through Lipid modification
CETP Cholesteryl ester transfer protein
CE Cholesteryl ester
LDL Low-density lipoprotein
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
POPC Palmitoyl-oleoyl phosphatidyl choline
SR-BI Scavenger receptor class B type I
SPM Sphingomyelin
SAA Serum amyloid A
CVD Cardiovascular Disease
ASCVD Atherosclerotic Cardiovascular Disease
FH Familial hypercholesterolemia
VCAM-1 Vascular cell adhesion molecule 1
MACE Major adverse cardiovascular events
MPO Myeloperoxidase
MCP-1 Monocyte chemotactic factor 1
PON1 Paraoxonase1
LXR Liver X receptors
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ROS Reactive oxygen species
I/R Ischemic reperfusion
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